Overview
Pharmaceutical

NIPPON CHEMIPHAR CO.,LTD.

Nippon Chemiphar is a Japanese pharmaceutical company primarily engaged in the manufacture and sale of prescription (ethical) pharmaceuticals, with additional operations in healthcare, beauty, and real estate leasing. The company is also advancing its own drug discovery pipeline, including a Phase IIa clinical trial for NC-2800, a delta opioid receptor agonist targeting depression. Its product portfolio includes generic and branded prescription drugs such as antithrombotics and antihypertensives, supported by manufacturing capabilities in Japan and Vietnam.

Market Cap
¥5.59B
US$35.6M
EV
¥14.8B
US$94.3M
Stock¥1,543▲+0.06%
US$1 = ¥157.05 (2026-10-22)
LTM EV/EBITDA
11.7
x
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
0.3
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-26.2%pt
1001
Oct 23, 25 – Oct 23, 26StockTOPIX
1Aug 3, 26Q1 FY2027/03 earnings announced
MC → EV Bridge
5.59BUS$35.6MMarket Cap18.5BUS$118M+ Debt7.06BUS$44.9M− Cash2.24BUS$14.2M− Inv. Sec.14.8BUS$94.3MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
32.5US$207M'22/331.6US$201M'23/330.7US$196M'24/332.6US$207M'25/333.1US$211M'26/3
EBITDA 5Y (¥B)
2.41US$15.4M'22/31.26US$8.02M'23/30.97US$6.14M'24/31.98US$12.6M'25/31.74US$11.1M'26/3
Net Income 5Y (¥B)
0.70US$4.46M'22/30.34US$2.16M'23/3-0.18-US$1.15M'24/30.29US$1.87M'25/30.20US$1.26M'26/3
Capital Structure
51%
49%
EquityD/E 0.96xDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
13.5US$85.7M14.6US$92.9M'22/311.9US$75.9M15.2US$97.0M'23/311.3US$71.7M17.0US$108M'24/38.94US$57.0M18.1US$115M'25/37.41US$47.2M16.6US$106M'26/3
Shareholders
Top 10 hold 50.0%
1
Japan Sofarshim Co., Ltd.
11.88%
2
Yamaguchi Memorial Foundation for Science Promotion (Public Interest Foundation)
8.22%
3
Toyoshima Pharmaceutical Co., Ltd.
6.63%
4
Nippon Life Insurance Company (Standing Proxy: The Master Trust Bank of Japan, Ltd.)
3.94%
5
Hitoshi IMAMURA
3.45%
6
NIPPON CHEMIPHAR CO.,LTD. Employee Stock Ownership Association
3.35%
7
ZERIA PHARMACEUTICAL CO.,LTD.
3.32%
8
Ueda Yagi Tanshi Co., Ltd.
3.25%
9
Issei YAMAGUCHI
3.04%
10
Reiko YAMAGUCHI
2.87%
Management
10 officers
Issei YAMAGUCHI
Representative Director, President, Representative Executive Officer, President
Apr 1981 Joined The Dai-Ichi Kangyo Bank, Ltd. Apr 1985 Joined the Company Jun 1987 Director Jun 1989 Managing Director Jun 1990 Representative Director, Senior Managing Director Jun 1993 Representative Director, Executive Vice President Jun 1994 Representative Director, President Jun 2001 Representative Director, President, Representative Executive Officer May 2005 Representative Director, President, Representative Executive Officer, President (current) Jun 2016 Representative Director, Japan Sofarshim Co., Ltd. (current)
1958-07-23
Masahide YASUMOTO
Director, Senior Managing Executive Officer; Assistant to Overall Management; in charge of Risk Management, Corporate Planning, IT Systems, and Clinical Diagnostics Business; General Manager, Healthcare Department
Apr 1991 Joined The Nippon Credit Bank, Ltd. Nov 2002 Joined KPMG Healthcare Japan Co., Ltd. Apr 2005 Joined the Company Oct 2007 General Manager, Corporate Planning Office Jul 2008 Executive Officer; in charge of Public Relations Office; General Manager, Corporate Planning Department Jun 2012 Director, Executive Officer; in charge of Administration, IT Systems, and Public Relations Office; General Manager, Corporate Planning Department Apr 2023 Director, Managing Executive Officer; in charge of IT Systems, Public Relations Office, and Clinical Diagnostics Business; General Manager, Corporate Planning Department and Healthcare Department Apr 2025 Director, Senior Managing Executive Officer; Assistant to Overall Management; in charge of Risk Management, Corporate Planning, IT Systems, and Clinical Diagnostics Business; General Manager, Healthcare Department (current)
1967-10-20
Yasunori HAYAMIZU
Director, Managing Executive Officer; in charge of Drug Discovery Research Laboratories, Development Planning, Formulation Technology Development, Overseas Business, and Medical Affairs
Apr 1988 Joined Yamanouchi Pharmaceutical Co., Ltd. Oct 2007 Joined Otsuka Pharmaceutical Co., Ltd. Nov 2013 Joined Mallinckrodt Japan K.K. Nov 2015 Joined Oncolys BioPharma Inc. Jul 2017 Joined the Company Apr 2018 General Manager, Development Planning Department Apr 2019 Executive Officer; General Manager, Development Planning Department Jun 2023 Director, Executive Officer; in charge of Medical Affairs; General Manager, Development Planning Department Apr 2025 Director, Managing Executive Officer; in charge of Drug Discovery Research Laboratories, Formulation Technology Development, Overseas Business, and Medical Affairs; General Manager, Development Planning Department Oct 2025 Director, Managing Executive Officer; in charge of Drug Discovery Research Laboratories, Development Planning, Formulation Technology Development, Overseas Business, and Medical Affairs (current)
1962-10-28
Shinji NAKAJIMA
Director, Executive Officer; in charge of Compliance and General Affairs, Legal Affairs, Group Purchasing, and Business Management Center; General Manager, Administration Department
Apr 1986 Joined Kinmon Seisakusho Co., Ltd. Apr 1998 Joined Daimler-Benz InterServices Telematics Japan K.K. Apr 2000 Joined the Company Apr 2012 General Manager, Administration Department Apr 2015 Executive Officer; General Manager, Administration Department Apr 2017 Executive Officer; in charge of Business Management Center; General Manager, Administration Department Apr 2019 Executive Officer; in charge of Purchasing and Logistics Center and Business Management Center; General Manager, Administration Department Jun 2025 Director, Executive Officer; in charge of Compliance and General Affairs, Group Purchasing, and Business Management Center; General Manager, Administration Department Apr 2026 Director, Executive Officer; in charge of Compliance and General Affairs, Legal Affairs, Group Purchasing, and Business Management Center; General Manager, Administration Department (current)
1962-12-20
Masami YOSHINO
Director
Apr 1985 Joined Ministry of Foreign Affairs Apr 1995 Registered as attorney-at-law (Dai-Ichi Tokyo Bar Association); joined Kajitani Sogo Law Office Apr 1996 Joined TMI Associates Jan 2002 Registered as attorney in New York State Jan 2003 Partner, TMI Associates Oct 2004 Joined Takegawa, Oka & Yoshino Law Office as Partner Jun 2007 Outside Audit & Supervisory Board Member, Shinkawa Ltd. Jul 2014 Established Yoshino Sogo Law Office (current) Jun 2019 Outside Director, the Company (current) Jun 2019 Outside Director (Audit and Supervisory Committee Member), Shinkawa Ltd. Sep 2019 Outside Director (Audit and Supervisory Committee Member), Pan Pacific International Holdings Corporation
1960-04-23
Naoko OMUKAI
Director
Oct 2002 Registered as attorney (Tokyo Bar Association); joined Asahi Komatsu Law Office (now Nishimura & Asahi) Apr 2005 Member, International Committee, Tokyo Bar Association Sep 2008 Registered as attorney in New York State Jun 2014 Outside Director, Prestige International Inc. Jun 2015 Infringement Determination Advisory Investigator, Ministry of Economy, Trade and Industry (current) Jul 2016 Member, Trademark System Subcommittee, Industrial Structure Council, Ministry of Economy, Trade and Industry Jul 2016 Deputy Chair, Design, Trademark and Unfair Competition Project Team, Intellectual Property Center, Japan Federation of Bar Associations Jul 2018 Director (part-time), Japan Trademark Association (current) Jan 2021 Partner, Nishimura & Asahi (current) Jun 2023 Outside Director, the Company (current) Jun 2023 Outside Director, Daido Life Insurance Company (current) Jul 2024 Member, Business Activities Review Committee, Japan Broadcasting Corporation Affiliated Organizations (current)
1974-12-30
Manabu NARITA
Director
Apr 1981 Joined The Sumitomo Bank, Ltd. Apr 2008 Executive Officer, Sumitomo Mitsui Banking Corporation Apr 2011 Managing Executive Officer, Sumitomo Mitsui Banking Corporation Apr 2013 Managing Executive Officer, Sumitomo Mitsui Financial Group, Inc. Jun 2013 Director, Sumitomo Mitsui Financial Group, Inc. Apr 2014 Director and Senior Managing Executive Officer, Sumitomo Mitsui Banking Corporation Apr 2015 Senior Managing Executive Officer, Sumitomo Mitsui Banking Corporation Mar 2017 Director and Senior Managing Executive Officer, Sumitomo Mitsui Banking Corporation Apr 2017 Deputy President Executive Officer, Sumitomo Mitsui Financial Group, Inc.; Director and Deputy President Executive Officer, Sumitomo Mitsui Banking Corporation Jun 2017 Executive Officer, Deputy President, Sumitomo Mitsui Financial Group, Inc. Apr 2019 Vice Chairman, Sumitomo Mitsui Financial Group, Inc.; Vice Chairman, Sumitomo Mitsui Banking Corporation Jun 2022 Representative Director, President, Ginsen Co., Ltd. Jun 2025 Outside Director, the Company (current) Jun 2025 Outside Director, Valqua, Ltd. (current) Jun 2025 Chairman of the Board, Ginsen Co., Ltd. (current)
1959-03-29
Sakari MAKINO
Full-time Audit & Supervisory Board Member
Apr 1984 Joined Josan Shinkin Bank Sep 1990 Joined Nagasakiya Co., Ltd. Apr 2000 Joined the Company Apr 2006 Section Manager, Administration Department Apr 2017 Internal Audit Section, Corporate Office; concurrently Administration Department Aug 2019 Assistant to Audit & Supervisory Board Members; concurrently Internal Audit Section, Corporate Office and Administration Department Jun 2020 Audit & Supervisory Board Member (current)
1960-01-22
Rumi YAMAGUCHI
Audit & Supervisory Board Member
Apr 1991 Joined Chuo Shinko Audit Corporation Mar 1994 Registered as Certified Public Accountant Aug 2007 Opened Rumi Yamaguchi CPA Office (current) Mar 2012 Registered as Tax Accountant; opened Rumi Yamaguchi Tax Accountant Office (current) Jun 2022 Outside Audit & Supervisory Board Member, the Company (current) Jun 2025 Outside Director (Audit and Supervisory Committee Member), Komori Corporation (current) Member, Council for National Research and Development Agencies, Ministry of Land, Infrastructure, Transport and Tourism (current)
1968-08-13
Tsuyoshi SHIBA
Audit & Supervisory Board Member
Aug 1986 Joined Chuo Kaikei Audit Corporation Mar 1989 Registered as Certified Public Accountant Jul 2005 Representative Partner, Chuo Aoyama Audit Corporation Sep 2006 Representative Partner, PwC Aarata LLC Jul 2013 Executive Managing Director, Japanese Institute of Certified Public Accountants Jun 2016 Auditor, Kato Memorial Bioscience Foundation (current) Jul 2019 Member, Expert and Practitioner Meeting on Certification under the Next-Generation Medical Infrastructure Act, Cabinet Office Sep 2020 Opened Tsuyoshi Shiba CPA Office (current) Jun 2021 Outside Audit & Supervisory Board Member, Industrial Decisions Inc. (now Exponential Design Inc.) (current) Jun 2024 Outside Audit & Supervisory Board Member, the Company (current)
1960-04-22
Large Shareholding Reports
Japan Sofarushimu Co., Ltd.
2026-08-05
9.72%→10.73%
Japan Sofarushimu Co., Ltd.
2025-12-05
16.76%→9.72%
Yamaguchi Memorial Science Promotion Foundation
2025-12-05
7.04%
Annual report (as of 2026-03-31): 8.22%
Japan Sofarushimu Co., Ltd.
2025-08-08
16.57%→16.76%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-05
Large Shareholding Report
TDnet
2026-07-31
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-15
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-01-30
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-12-05
Large Shareholding Report
EDINET
2025-12-05
Large Shareholding Report
EDINET
2025-11-13
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-08-08
Large Shareholding Report
TDnet
2025-07-31
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-20
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-01-31
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-07-31
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-24
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-13
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-22
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-13
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-09
Quarterly Securities Report
EDINET
2022-06-27
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-11
Quarterly Securities Report
EDINET
2021-06-21
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →